Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Incyte Corp Announces Positive Results From Proof-Of-Concept Phase II Clinical Trial Of Incyte’s Oral JAK1 Inhibitor In Patients With Active Rheumatoid Arthritis


Monday, 28 Oct 2013 10:16pm EDT 

Incyte Corp announced results from a 12-week, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 60 patients with active rheumatoid arthritis for oral JAK1 inhibitor. In the initial Phase II trial, 12 weeks of treatment with INCB39110 showed efficacy at all doses as measured by ACR 20, ACR 50, ACR 70, and DAS 28 as compared to placebo. Clinical benefit was observed as early as one week of treatment, and the highest dose tested, once-daily 600 mg, appeared to be the effective dose. The primary endpoint of the study was the proportion of patients who achieved an ACR 20 at week 12. Secondary endpoints at week 12 included the proportion of patients who achieved ACR 50 or ACR 70, the mean change from baseline in DAS 28 score, and the proportion of patients who achieved a DAS 28 score of < 2.6. 

Related Company News

Company Quote

54.2
0.26 +0.48%
29 Aug 2014